Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1

Weizao Chen, Ariola Bardhi, Yang Feng, Yanping Wang, Qianqian Qi, Wei Li, Zhongyu Zhu, Marzena A. Dyba, Tianlei Ying, Shibo Jiang, Harris Goldstein, Dimiter S. Dimitrov

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

We previously described 4Dm2m, an exceptionally potent broadly neutralizing CD4-antibody fusion protein against HIV-1. It was generated by fusing the engineered single human CD4 domain mD1.22 to both the N and C termini of the human IgG1 heavy chain constant region and the engineered single human antibody domain m36.4, which targets the CD4-induced coreceptor binding site of the viral envelope glycoprotein, to the N terminus of the human antibody kappa light chain constant region via the (G4S)3 polypeptide linkers. However, therapeutic use of 4Dm2m was limited by its short in vivo half-life. Here, we show that a combination of three approaches have successfully increased the persistence of 4Dm2m in mice. First, to stabilize the scaffold, we enhanced heterodimerization between the heavy chain constant domain 1 (CH1) and kappa light chain constant domain (CK) by using structure-guided design and phage-display library technologies. Second, to address the possibility that long polypeptide linkers might render fusion proteins more susceptible to proteolysis, we shortened the (G4S)3 linkers or replaced them with the human IgG1 hinge sequence, which is naturally designed for both flexibility and stability. Third, we introduced two amino acid mutations into the crystallizable fragment (Fc) of the scaffold previously shown to increase antibody binding to the neonatal Fc receptor (FcRn) and prolong half-lives in vivo. Collectively, these approaches markedly increased the serum concentrations of 4Dm2m in mice while not affecting other properties of the fusion protein. The new 4Dm2m variants are promising candidates for clinical development to prevent or treat HIV-1 infection. To our knowledge, this is the first report on stabilized CH1-CK, which is potentially useful as a new heterodimerization scaffold for generation of bispecific and multispecific antibodies or proteins with a more favorable pharmacokinetic profile.

Original languageEnglish (US)
Pages (from-to)761-774
Number of pages14
JournalmAbs
Volume8
Issue number4
DOIs
StatePublished - May 18 2016

Fingerprint

HIV-1
Pharmacokinetics
Antibodies
Proteins
Single-Domain Antibodies
Immunoglobulin G
Bispecific Antibodies
Immunoglobulin Fc Fragments
Light
Peptides
Therapeutic Uses
Neutralizing Antibodies
Bacteriophages
Proteolysis
Libraries
HIV Infections
Half-Life
Glycoproteins
Binding Sites
Technology

Keywords

  • 4Dm2m
  • Antibody
  • CH1-CK
  • FcRn
  • Fusion proteins
  • Heterodimerization
  • HIV-1
  • Linker
  • Pharmacokinetics
  • Soluble CD4

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1. / Chen, Weizao; Bardhi, Ariola; Feng, Yang; Wang, Yanping; Qi, Qianqian; Li, Wei; Zhu, Zhongyu; Dyba, Marzena A.; Ying, Tianlei; Jiang, Shibo; Goldstein, Harris; Dimitrov, Dimiter S.

In: mAbs, Vol. 8, No. 4, 18.05.2016, p. 761-774.

Research output: Contribution to journalArticle

Chen, W, Bardhi, A, Feng, Y, Wang, Y, Qi, Q, Li, W, Zhu, Z, Dyba, MA, Ying, T, Jiang, S, Goldstein, H & Dimitrov, DS 2016, 'Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1', mAbs, vol. 8, no. 4, pp. 761-774. https://doi.org/10.1080/19420862.2016.1160180
Chen, Weizao ; Bardhi, Ariola ; Feng, Yang ; Wang, Yanping ; Qi, Qianqian ; Li, Wei ; Zhu, Zhongyu ; Dyba, Marzena A. ; Ying, Tianlei ; Jiang, Shibo ; Goldstein, Harris ; Dimitrov, Dimiter S. / Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1. In: mAbs. 2016 ; Vol. 8, No. 4. pp. 761-774.
@article{88e07195a7564c488df21268789a8488,
title = "Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1",
abstract = "We previously described 4Dm2m, an exceptionally potent broadly neutralizing CD4-antibody fusion protein against HIV-1. It was generated by fusing the engineered single human CD4 domain mD1.22 to both the N and C termini of the human IgG1 heavy chain constant region and the engineered single human antibody domain m36.4, which targets the CD4-induced coreceptor binding site of the viral envelope glycoprotein, to the N terminus of the human antibody kappa light chain constant region via the (G4S)3 polypeptide linkers. However, therapeutic use of 4Dm2m was limited by its short in vivo half-life. Here, we show that a combination of three approaches have successfully increased the persistence of 4Dm2m in mice. First, to stabilize the scaffold, we enhanced heterodimerization between the heavy chain constant domain 1 (CH1) and kappa light chain constant domain (CK) by using structure-guided design and phage-display library technologies. Second, to address the possibility that long polypeptide linkers might render fusion proteins more susceptible to proteolysis, we shortened the (G4S)3 linkers or replaced them with the human IgG1 hinge sequence, which is naturally designed for both flexibility and stability. Third, we introduced two amino acid mutations into the crystallizable fragment (Fc) of the scaffold previously shown to increase antibody binding to the neonatal Fc receptor (FcRn) and prolong half-lives in vivo. Collectively, these approaches markedly increased the serum concentrations of 4Dm2m in mice while not affecting other properties of the fusion protein. The new 4Dm2m variants are promising candidates for clinical development to prevent or treat HIV-1 infection. To our knowledge, this is the first report on stabilized CH1-CK, which is potentially useful as a new heterodimerization scaffold for generation of bispecific and multispecific antibodies or proteins with a more favorable pharmacokinetic profile.",
keywords = "4Dm2m, Antibody, CH1-CK, FcRn, Fusion proteins, Heterodimerization, HIV-1, Linker, Pharmacokinetics, Soluble CD4",
author = "Weizao Chen and Ariola Bardhi and Yang Feng and Yanping Wang and Qianqian Qi and Wei Li and Zhongyu Zhu and Dyba, {Marzena A.} and Tianlei Ying and Shibo Jiang and Harris Goldstein and Dimitrov, {Dimiter S.}",
year = "2016",
month = "5",
day = "18",
doi = "10.1080/19420862.2016.1160180",
language = "English (US)",
volume = "8",
pages = "761--774",
journal = "mAbs",
issn = "1942-0870",
publisher = "Landes Bioscience",
number = "4",

}

TY - JOUR

T1 - Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1

AU - Chen, Weizao

AU - Bardhi, Ariola

AU - Feng, Yang

AU - Wang, Yanping

AU - Qi, Qianqian

AU - Li, Wei

AU - Zhu, Zhongyu

AU - Dyba, Marzena A.

AU - Ying, Tianlei

AU - Jiang, Shibo

AU - Goldstein, Harris

AU - Dimitrov, Dimiter S.

PY - 2016/5/18

Y1 - 2016/5/18

N2 - We previously described 4Dm2m, an exceptionally potent broadly neutralizing CD4-antibody fusion protein against HIV-1. It was generated by fusing the engineered single human CD4 domain mD1.22 to both the N and C termini of the human IgG1 heavy chain constant region and the engineered single human antibody domain m36.4, which targets the CD4-induced coreceptor binding site of the viral envelope glycoprotein, to the N terminus of the human antibody kappa light chain constant region via the (G4S)3 polypeptide linkers. However, therapeutic use of 4Dm2m was limited by its short in vivo half-life. Here, we show that a combination of three approaches have successfully increased the persistence of 4Dm2m in mice. First, to stabilize the scaffold, we enhanced heterodimerization between the heavy chain constant domain 1 (CH1) and kappa light chain constant domain (CK) by using structure-guided design and phage-display library technologies. Second, to address the possibility that long polypeptide linkers might render fusion proteins more susceptible to proteolysis, we shortened the (G4S)3 linkers or replaced them with the human IgG1 hinge sequence, which is naturally designed for both flexibility and stability. Third, we introduced two amino acid mutations into the crystallizable fragment (Fc) of the scaffold previously shown to increase antibody binding to the neonatal Fc receptor (FcRn) and prolong half-lives in vivo. Collectively, these approaches markedly increased the serum concentrations of 4Dm2m in mice while not affecting other properties of the fusion protein. The new 4Dm2m variants are promising candidates for clinical development to prevent or treat HIV-1 infection. To our knowledge, this is the first report on stabilized CH1-CK, which is potentially useful as a new heterodimerization scaffold for generation of bispecific and multispecific antibodies or proteins with a more favorable pharmacokinetic profile.

AB - We previously described 4Dm2m, an exceptionally potent broadly neutralizing CD4-antibody fusion protein against HIV-1. It was generated by fusing the engineered single human CD4 domain mD1.22 to both the N and C termini of the human IgG1 heavy chain constant region and the engineered single human antibody domain m36.4, which targets the CD4-induced coreceptor binding site of the viral envelope glycoprotein, to the N terminus of the human antibody kappa light chain constant region via the (G4S)3 polypeptide linkers. However, therapeutic use of 4Dm2m was limited by its short in vivo half-life. Here, we show that a combination of three approaches have successfully increased the persistence of 4Dm2m in mice. First, to stabilize the scaffold, we enhanced heterodimerization between the heavy chain constant domain 1 (CH1) and kappa light chain constant domain (CK) by using structure-guided design and phage-display library technologies. Second, to address the possibility that long polypeptide linkers might render fusion proteins more susceptible to proteolysis, we shortened the (G4S)3 linkers or replaced them with the human IgG1 hinge sequence, which is naturally designed for both flexibility and stability. Third, we introduced two amino acid mutations into the crystallizable fragment (Fc) of the scaffold previously shown to increase antibody binding to the neonatal Fc receptor (FcRn) and prolong half-lives in vivo. Collectively, these approaches markedly increased the serum concentrations of 4Dm2m in mice while not affecting other properties of the fusion protein. The new 4Dm2m variants are promising candidates for clinical development to prevent or treat HIV-1 infection. To our knowledge, this is the first report on stabilized CH1-CK, which is potentially useful as a new heterodimerization scaffold for generation of bispecific and multispecific antibodies or proteins with a more favorable pharmacokinetic profile.

KW - 4Dm2m

KW - Antibody

KW - CH1-CK

KW - FcRn

KW - Fusion proteins

KW - Heterodimerization

KW - HIV-1

KW - Linker

KW - Pharmacokinetics

KW - Soluble CD4

UR - http://www.scopus.com/inward/record.url?scp=84971408155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971408155&partnerID=8YFLogxK

U2 - 10.1080/19420862.2016.1160180

DO - 10.1080/19420862.2016.1160180

M3 - Article

VL - 8

SP - 761

EP - 774

JO - mAbs

JF - mAbs

SN - 1942-0870

IS - 4

ER -